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 Complex between BI-224436 and HIV-1 integrase was used to design novel anti-HIV 
inhibitors.  
 The de novo approach available in LigBuilder was used. 
 A number of criteria was used to narrow down the chemical space of initial designed 80000 
inhibitors. 
 Different pharmacokinetics parameters were checked for final proposed molecules. 
 MD simulation was performed of HIV-1 integrase complex with proposed molecules. 





In the present study, pharmacoinformatics paradigms include receptor-based de novo design, 









implemented to identify novel and promising HIV-1 integrase inhibitors. The de 
novo drug/ligand/molecule design is a powerful and effective approach to design a large 
number of novel and structurally diverse compounds with the required pharmacological 
profiles. A crystal structure of HIV-1 integrase bound with standard inhibitor BI-224436 is 
used and a set of 80000 compounds through the de novo approach in LigBuilder is designed. 
Initially, a number of criteria including molecular docking, in-silico toxicity and 
pharmacokinetics profile assessments are implied to reduce the chemical space. Finally, four 
de novo designed molecules are proposed as potential HIV-1 integrase inhibitors based on 
comparative analyses. Notably, strong binding interactions have been identified between a 
few newly identified catalytic amino acid residues and proposed HIV-1 integrase inhibitors. 
For evaluation of the dynamic stability of the protein-ligand complexes, a number of 
parameters are explored from the 100ns MD simulation study. The MD simulation study 
suggested that proposed molecules efficiently retained their molecular interaction and 
structural integrity inside the HIV-1 integrase. The binding free energy is calculated through 
the Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) approach for all 
complexes and it also explains their thermodynamic stability. Hence, proposed molecules 
through de novo design might be critical to inhibiting the HIV-1 integrase. 
 
Keywords: HIV-1 Integrase; De novo design; Virtual screening; Molecular docking; 
Molecular dynamics; MM-PBSA 
 
1. Introduction 
The Human Immune deficiency Virus (HIV) infections can lead to the acquired immune 
deficiency syndrome (AIDS) which is a medical condition and can be simply labeled as a 
curse upon the human race. The progression of HIV infection is highly variable and depends 
on the individual’s immune system [1].  HIV infection continues to be a major global public 
health concern, as estimated by approximately 37.9 million people (according to the report of 
World Health Organization) living with HIV till the end of 2018 [2]. Among all, 
approximately 25.7 million people are living with HIV in the African Region. Moreover, at 
the end of the year 2018, 62% of HIV infected people received antiretroviral therapy (ART). 
Most recent data indicates that about 24.5 million people accessed ART during June 2019. 
However, due to long-term extensive gaps in HIV management and awareness services, 
approximately 0.7 million people died from HIV-associated causes in 2018 [2]. As of now, 









can only control or suppress the HIV virus and subsequently help to prevent onward 
transmission to other individuals [3, 4]. There are several numbers of ARVs, and they can be 
combined with different ways for treating HIV without any restrictions of CD4 counts [1].  
In the current study, an attempt has been taken to identify potential anti-retroviral modulator 
or inhibitor hits against the HIV-1 integrase protein using computational multiple molecular 
modeling approaches. The HIV-1 integrase protein is one of the essential enzymes which 
drives viral replication processes and also responsible for the obligatory integration of viral 
DNA into the host chromosome via covalent insertion [5-8]. Thus for long decades, the HIV-
1 integrase has been considered to be an experimentally well-validated target for clinically 
effective anti-AIDS therapeutics developments. It can also be effective to manage against 
drug-resistant mutants HIV infections [6, 9-13]. In general, HIV-1 integrase is comprised of 
three distinct functional domains: the C-terminal domain (CTD), the catalytic core domain 
(CCD), and the N-terminal domain (NTD) [14, 15]. Each domain has distinct characteristics 
such as NTD region (residues 1-50) contains high conserved His and Cys amino acid residues 
(or HHCC motif) and known to help in chelation of zinc ion. The CCD region of HIV-1 
integrase, spanning amino acids 51–212, contains endonuclease site as well as highly 
conserved acidic amino acid residues such as Asp64, Asp116 and Glu152 (known as DDE 
motif). The CDD is considered to be an important instrumental part that is conserved among 
all retroviral integrase proteins. Majorly, this CCD region of HIV-1 integrase contains the 
enzyme catalytic site(s) [16]. Any mutation in these residues diminishes the catalytic activity. 
Indeed, all three domains cooperate for the variety of the enzymatic functions catalyzed by 
the integrase protein [17]. On the other hand, CTD region (amino acid residues: 213–288) 
specifically plays a role in DNA binding and is responsible for stabilizing the DNA-protein 
complex once bonded with DNA [15]. In the present scenario, comparison to understanding 
the role of CCD region, the biological role of NTD and CTD regions are less understood. 
Although, it is known that all three domains are essential and responsible for 3’-p processing 
and strand transfer activity. In this study, comprehensively emphasis has been given on CCD 
region of integrase which plays an indispensable role for demonstrating integrase-mediated 
enzymatic activities [18]. Moreover, the HIV integrase protein can exists in dimer or in 
higher oligomeric states but their structural and functional aspects are yet under the research 
and developmental phase. Moreover, for the last two decades, the CCD region of integrase 
has been under special attention for assisting and expediting the future drug design efforts 
[19, 20]. Although, integrase strand transfer inhibitors (INSTIs) target the HIV-1 integrase 








effects pose striking challenges to INSTI-based therapies moving ahead [21]. Among various 
clinically available INSTIs, such as Raltegravir, Elvitegravir, and Dolutegravir are now being 
used in clinical practice [22-25]. These drugs also show adverse or toxic, neuropsychiatric, 
osteomuscular or digestive complications [26, 27]. Moreover, INSTI-resistant mutants can 
also emerge during treatment, that can cause resistance to the approved first-generation 
INSTIs [28-31]. Resistance mutations usually take place in proximal to the HIV-1  integrase 
active site, primarily in the β4α2 loop of the CCD [9]. Such instances motivate the 
researchers to continue to study the mechanisms of HIV drug resistance and develop novel 
therapeutics, a top priority for HIV research. Previously, a number of experimental as well as 
computational approaches were undertaken precisely targeting the HIV-1 integrase to identify 
promising chemical entities that can provide therapeutic and preventive regimes or can act as 
antiretroviral therapy and vaccines for managing HIV/AIDS infection [20, 32-46]. However, 
complete eradication of HIV infection is a daunting objective that requires definitive 
treatment strategies which are still missing.  
In the present era of pharmaceutical development for novel drug discovery, besides the high-
throughput virtual screening, the de novo drug/ligand design technique is getting much faster 
attention as one of the finest complementary tools [47-50]. Most importantly, the significant 
elicitation of the de novo design methodology is a novel molecular structure generation 
method with very low cost and less time taking in comparison to the traditional drug 
discovery techniques [51, 52]. Herein, in order to find few potential novel HIV-1 integrase 
inhibitors, the receptor-based de novo drug design technique is employed using the 
LigBuilder tool followed by virtual screening carried out through molecular docking and 
molecular dynamics (MD) simulations studies. Finally, the binding free energies of the final 
molecules are estimated. Additionally, the important residues of HIV-1 integrase protein have 
already been reported which participate in hydrogen bond (H-bond) and non-H-bond 
interactions crucial for blocking the integrase activity. Finally, the study has reported four 
structurally diverse compounds designed through the de novo technique capable to decipher 
strong molecular interactions with viral HIV-1 integrase protein. Hence, reported chemical 
entities identified through extensive de novo design techniques can optimally block the 
integrase activity and therefore capable to opt for developing a next-generation newer class of 
HIV-1 integrase inhibitors subjected to experimental validation.  
 









The crystal structure of the HIV-1 integrase was obtained from the RCSB-Protein Data Bank 
(PDB) having PDB ID 6NUJ (53). This is the most recently resolved crystalized HIV-1 
integrase (CCD) with resolution and R-value of 2.1 Å and 0.244 respectively. In order to 
select the HIV-1 integrase few parameters were checked included resolution, date of 
deposition in the PDB and bound small molecule. The selected HIV-1 integrase was found to 
be consisting of 166 amino acid residues. The standard HIV-1 integrase inhibitor, BI-224436 
was bound inside the CCD of the selected protein. The quinoline-based compound, BI-
224436 is a first non-catalytic site HIV-1 integrase inhibitor having an effective antiviral 
activity (54). It is reported that the BI-224436 inhibits HIV replication through association at 
the conserved allosteric pocket of the HIV integrase enzyme. The molecular weight and exact 
mass of the BI-224436 are reported as 442.50 and 442.18 g/mol, respectively. Throughout the 
study, BI-224436 was selected as a control compound and used for a comparative 
perspective. The position of catalytic and allosteric sites of HIV-1 integrase protein were 
identified and it is given in Figure S1 (Supplementary data). 
 
2.1 Molecular docking  
Prior to molecular docking, it is essential to prepare the protein and ligands. The HIV-1 
integrase enzyme was prepared in the graphical user interface program AutoDock Tool 
(ADT) (55). The missing atoms and side chains were checked and subsequently repaired in 
protein structure. A number of required polar hydrogens were added to the protein structure. 
The Gasteiger charge was assigned. The prepared protein was saved in .pdbqt file format for 
further uses. For the preparation of the standard ligand, BI-224436 was first re-drawn using 
MarvinSketch (v. 17.8.0) and followed by the addition of hydrogen atoms and a required 
number of active torsions were assigned. Re-drawing of the standard compound was carried 
out to accurately get the optimized chemical structure which must be needed in docking 
study. Similar to the protein structure, the Gasteiger charge was also adjusted to the standard 
compound. Finally, the standard compound BI-224436 was saved as .pdbqt file format. Such 
a specific file format is required for the input file in Autodock Vina during docking 
execution. Simultaneously, for the large number of generated HIV-1 integrase inhibitors 
designed through de novo technique were also converted into .pdbqt format using the 
OpenBabel (56), a freely available file format conversion tool. During the structural 
conversion, the appropriate number of hydrogen atoms were added and charge adjusted to 
each ligand. The grid was generated by confining the bound ligand BI-224436. The grid 









axes, respectively. The size of the grid box dimension was set to   60Å x 60Å x 60Å. The 
prepared protein and ligands along with the grid information were kept in a configuration file 
that was considered for molecular docking study in AutoDock Vina (ADV) tool (57) installed 
in the CHPC server at Cape Town, South Africa (https://www.chpc.ac.za/). During the 
execution of molecular docking, the protein structure was retained as rigid, while the ligand 
structures were considered as flexible. However, firstly to validate the molecular docking 
protocol, the self-docking approach was used. In this method, the bound standard ligand (BI-
224436) was re-docked in the same active site cavity of HIV-1 integrase where it was 
originally attached.  It is reported that the root means square deviation (RMSD) less than 2 Å 
between best docked pose and crystalized ligand can predict the perfect orientation of any 
small molecule (58). After self-docking, the re-docked best pose of  BI-224436 was extracted 
and superimposed with the original crystalized pose of the same and subsequently RMSD 
was calculated. In the present study, generated docked poses for all the designed compounds 
and their binding energies were explored to analyze the molecular docking outcomes. 
Thereafter, binding interactions in 2D and 3D-space were explored through the Maestro 
interface of Schrodinger and PyMol. 
 
2.2 De novo design using LigBuilder tool 
Among several structure-based drug design (SBDD) and ligand-based drug design (LBDD) 
approaches, the de novo design technique is one of the crucial and pivotal methods to build 
small molecules with desired pharmacological properties. In the de novo design technique, 
the 3D structure of the receptor was used to design a large number of newer molecules with 
high potential and therapeutic value. A common phenomenon of de novo design technique is 
the generation of large ligands as the greater molecular size inclines to accomplish the higher 
binding affinity (59). However, the fact is, sometimes it may produce false-positive outcomes 
as well due to size/shape and negligence of molecular interactions complementarity between 
protein and ligand. Keeping that view in consideration, in the current study, widely accepted 
LigBuilder v2.0  - an open-source de novo library designed tool (60) which follows genetic 
algorithm to construct ligands library, was used to design the HIV-1 integrase inhibitors. 
Precisely, LigBuilder is a highly acknowledged multi-purposed tool used for structure-based 
de novo drug design and optimization. LigBuilder can automatically build-up ligand 
compounds within the user defined binding pocket and subsequently screen them based on 
the 3D structure of the target protein. Herein, the 3D crystal structure of the HIV-1 integrase 








three features to follow and the execution of LigBuilder to generate the de novo molecules. In 
general, LigBuilder required a material library as input. In this purpose the large chemical 
database, ZINC was used as the material library. The LigBuilder has two main functional 
modules for execution, i.e. ‘cavity’ and ‘build’. The ‘cavity’ module takes the receptor and 
best scoring small molecules in .pdb and .mol2 format respectively. Herein, the ‘cavity’ 
module was used to analyze the binding pocket of the given HIV-1 integrase protein and 
prepared the data which are necessary to execute the ‘build’ module. The ‘build’ is the main 
functional module for de novo design and results analysis. The major function of ‘build’ 
module is the construction of ligand molecules for the target protein by applying the 
fragment-based design strategy. Although 'build' module relies on the binding-site describing 
in the file generated by 'cavity' module, however, it can take care of most inclusive 
parameters such lead optimization, fragment linking, design mimicking, binding-affinity 
estimation, ligand filtering, ligand recommendation, synthesis analysis, substructure search, 
and molecule clustering, etc. In the current study, out of available three modes available in 
the LigBuilder program such as ‘growing’, ‘linking’ and ‘exploring’, the ‘exploring’ mode 
was used to automatically generate the compounds. Firstly, the ‘cavity’ module was executed 
which derives few key interaction sites inside the binding site and, based on that, it suggests 
potential pharmacophore features. Further, the ‘build’ module was executed to generate the 
molecules with a given number of parameters including the number of generation, population 
size and the maximal number of outputs. In the current effort, the design number of 
generation was given as 80000. Hence, after successful completion, the LigBuilder was 
generated a total of 80000 new chemical components as HIV-1 integrase inhibitors. All 
generated compounds were checked carefully in terms of structural redundancy and similarity 
or dissimilarity before further assessment.     
 
2.3 Virtual screening strategies 
Virtual screening is an in-silico approach to find out the promising chemical entities from a 
large dataset for a specific target. The molecules designed in the de novo design approach 
targeting the HIV-1 integrase were further screened through the molecular docking, drug-
likeness and in-silico pharmacokinetics analyses. Initially, all generated molecules were 
checked for Lipinski’s rule of five (LoF) (61) and Veber’s rule (62). The LoF explains the 
drug-likeness characteristics of the molecules having the hydrophobicity less than 5, 
molecular weight less than 500, hydrogen bond (HB) donor and acceptor less than 5 and 10 









through Veber’s rule. According to this rule, being a potential molecule the total polar surface 
area (TPSA) and the number of rotatable bonds should not be more than 140Å2 and 10 
respectively. Further, the binding energy of the BI-224436 was used as a threshold to reduce 
the chemical space of remaining molecules from the previous step. Molecules having binding 
energy value higher than BI-224436 were discarded for further study. The toxic and 
environmental effects of the molecules were checked through the TOxicity Prediction by 
Komputer Assisted Technology (TOPKAT) module available in Discovery Studio. The 
TOPKAT predicts the toxic and environmental effects of the chemical substances through 
cross-validated quantitative structure toxicity relationship (QSTR) models. Molecules 
showed toxic, mutagenic, irritant and carcinogenic were removed for further analysis. 
Finally, molecules remained after TOPKAT assessment were used to calculate a number of 
pharmacokinetics parameters including n-octanol and water (log Po/w) partition coefficient or 
lipophilicity, molar solubility in water, blood-brain barrier (BBB) permeability, skin 
permeation and human gastrointestinal absorption (HIA) capability. On detained analysis, the 
molecules showed good absorption, distribution, metabolism and excretion were proposed as 
promising HIV-1 integrase inhibitors.  
A number of drug-likeness properties included ligand efficiency (LE), ligand efficiency scale 
(LE_scale), fit quality (FQ), and LE-dependent lipophilicity(LELP) were explored to assess 
the potentiality of the molecules. First of all, the LE given by Hopkins et al. (63) was 
calculated as per equation (1). This parameter is the negative ratio between binding energy 





         (1) 
The LE_Scale is the size-dependent comparison of the small molecules given by Reynolds et 
al. (64) known as LE_Scale and can be calculated using equation (2). 
0.026_ 0.873 0.064NHALE Scale e       (2) 
Another crucial parameter, the fit quality score was calculated by equation (3). The FQ  





       (3) 
Finally, the LELP was calculated by equation (4). This parameter was proposed by Keseru 















2.4 Molecular dynamics simulation and binding free energy through MM-PBSA 
It is a matter of worth exploring the physical basis of the small molecule inside the protein 
and the dynamic evolution of the protein-ligand complex through MD simulation study. Each 
of the final proposed inhibitors bound with HIV-1 integrase was considered for MD 
simulation study for a time of span of 100ns. The MD simulation was carried out in the 
Gromacs 2018-2 available at the Lengau CHPC server with the time step, constant pressure 
and constant temperature value of 2 fs, 1 atm and 300 K respectively. The ligand topology 
was generated through the online freely available SwissParam tool (66). In the case of protein 
topology, the all-atom CHARMM36 force field (67) was used. The simulation system was 
built confining the protein-ligand complex within a cubic box with a diameter of 1Å from the 
center of the system. The entire simulation was performed in the water solvent and the TIP3P 
water model was used to solvate the system. A sufficient number of required ions, either Na+ 
or Cl- were added to neutralize the system. The system was minimized using the Steepest 
descent algorithm(68) to overcome the close-contacts or overlaps between the atoms. In order 
to equal distribution of the solvent and ions around the protein-ligand ligand complex, the 
entire system was equilibrated with NVT (constant number of particles, volume, and 
temperature) followed by NPT (constant number of particles, pressure, and temperature) 
ensemble approaches. To address the long-range interaction parameter the van der Waals and 
electrostatic the cut off were used to 0.9 and 1.4 nm respectively. The trajectory information 
was updated in 1ps interval. Different parameters including RMSD, root-mean-square 
fluctuation (RMSF) and radius of gyration (Rg) were calculated from the entire trajectory of 
MD simulation to explore the behavior of the molecules in the dynamic states. Further, the 
binding affinity of the molecules was analyzed by the evaluation of binding free energy 
obtained through the MM-PBSA (Molecular Mechanics Poisson-Boltzmann Surface Area) 
approach (69). The methodology of the MM-PBSA-based binding free energy calculation can 
be found somewhere else (70).  
 
3. Results and discussion 
3.1 De novo design and virtual screening 
In order to design novel chemical entities against the HIV-1 integrase infection, the de novo 
designed based virtual screening study is performed. The flow diagram of the study is given 
in Figure 1. The best-docked complex between the HIV-1 integrase and BI-224436 at the 









novo design approach. On successful completion of the de novo design in the LigBuilder 
program [60], a total of 80000 molecules are generated. The valance or representation errors 
are initially checked in a two-dimensional representation. It is found that very few molecules 
are generated with any such above errors. It is also found that most of the molecules are 
structurally diverse in nature. The entire set of the structure has been considered to check the 
duplicates and redundant molecules. On the deletion of duplicates, a total of 63112 molecules 
remained as structurally unique. The above compounds are allowed to check LoF and 
Veber’s rule, and it is found that 19927 molecules failed to pass through the above rules and 
subsequently removed. The remaining 43185 molecules are taken forward to dock with HIV-
1 integrase using the ADV tool [57].  
 
 
Figure 1. Flow diagram of de novo design based virtual screening 
 
Additionally, the standard compound BI-224436 has been docked in similar fashion which 
reveals the binding affinity score to be -6.60 Kcal/mol and subsequently considers it as the 
threshold value for further molecular screening. The binding energy is explored and 11454 
molecules are found to have binding energy less than the threshold (-6.60 Kcal/mol). A 
number of parameters of the above molecules have been generated through the TOPKAT to 









mutagenic, carcinogenic and irritant properties only 42 molecules are retained. Finally, the 
binding interactions and pharmacoinformatics parameters of each of the 42 molecules have 
been explored carefully. Particularly, accounting critical analysis, several important 
parameters such as H-bond energies, glide ligand efficiency scores, ligand binding free 
energies, the total number of intermolecular interactions present between HIV-1 integrase and 
designed compounds are recorded for selecting the potential inhibitors compounds. Not only 
that, different bio- and physicochemical parameters are also obtained in terms of molecular 
weight, number of heavy atoms, number of aromatic heavy atoms, number of rotatable bonds, 
molar refractivity, topological polar surface area, solubility class/scores, etc. for all 
compounds and analyzed extensively for separating the compounds with more suitable drug-
like characteristics. Finally, based on the above-mentioned parameters and acceptable 
pharmacokinetics profile data, four molecules are proposed as promising HIV-1 integrase 
inhibitors. To adjudge the uniqueness of the selected molecules, publicly available databases 
such as PubChem and ChemSpider chemical databases are searched through ‘Exact Match’ 
or ‘Identical Structure’ search method. Not a single identical molecule is found from the 
above databases which substantiate the uniqueness of the molecule. Two-dimensional 




Figure 2. Final selected de novo designed HIV-1 integrase inhibitors 
 









Firstly, to investigate the docking interaction analysis for the standard compound BI-224436, 
the interaction profile of original co-crystallized ligand has been extracted in NGL Viewer 
[71] (Figure 3A), which is directly linked with the PDB. In addition to the above re-docking 
protocol has also been critically executed. The binding interaction mode of the re-docked 
ligand is compared with co-crystallized ligand’s interaction mode by superimposing the 
protein-ligand complex crystal structure to each other (Figure 3B). In docking analyses, it is 
quite interesting to observe that the re-docking protocol successfully generates the exact or 
alike molecular interaction mode as co-crystallized ligand hold tightly (Figure 3C). For 
instance, in re-docking, the standard compound shows the similar hydrogen bonding 
interaction pattern (Figure 3C) which perfectly adjudges with the HIV-1 integrase residues 
(Glu170, His171 and Thr174) involved in H-bond interactions within the v-shaped pocket of 
HIV-1 integrase that is experimentally explained [53, 72]. Moreover, the RMSD value of 
superimposed re-docked ligand has been noted as 0.27Å, which undoubtedly acknowledges 
the accurate validation of the executed docking protocol employed in the present study. The 











Figure 3. Docking interaction analysis of the standard compound BI-224436. A: PDB 
extracted molecular interaction profile for original co-crystallized standard compound  BI-
224436 and HIV-1 integrase protein. B: Illustration of  the redocking ligand pose (light blue) 
and the original ligand pose in the co-crystallized structure (green). The HIV-1 integrase is 
shown in cartoon representation (light orange). C: 2D interaction map obtained in docking 
for the standard compound (BI-224436) with HIV-1 integrase protein. D: 
Superimposition of  the redocking ligand pose (deep blue) and the original ligand pose in the 
co-crystallized structure (green). Superimposed RMSD value is 0.27. 
 
Docking results of all four designed ligands with HIV-1 integrase protein in 2D interactions 
map are displayed in Figure 4. Moreover, to understand the better orientation of the docked 
molecule in the receptor cavity the binding mode in 3D framework is given in Figure 5. The 









bond and one π-π stacking interactions. Amino acid residues Glu87 and Asn184 are involved 
in H-bond formation and Phe181 formed π-π stacking interaction with H1. The HIV-1 
integrase and H1 docking complex exhibits the binding affinity score of -6.90 Kcal/mol. It 
has been revealed that H2 formed two H-bond interactions with residues Ala86 and Gln177 
of HIV-1 integrase protein. Apart from the above involvements other two amino acid residues 
(Tyr83 and Phe181) are also found which form pi-pi (π-π) stacking interactions with HIV-1 
integrase protein. The H-bond interactions with integrase protein are mediated by the 
association with –OH group of the designed ligand H2; whereas the aromatic ring present in 
H2 attributes the formation of π-π stacking interactions. In docking analyses, the binding 
affinity score between HIV-1 integrase and H2 is found to be -7.00 Kcal/mol. The molecular 
interaction profile between H3 and HIV-1 integrase has been investigated which reveals two 
H-bond interactions with residues Val113 and Gln138. The terminal oxygen atom and –OH 
group present in H3 participate to form such interaction profiles with HIV-1 integrase 
protein. The docking based binding affinity value is found to be -6.60 and -6.60 Kcal/mol for 
H3 and H4 respectively. The carboxylated oxygen atom of H4 forms H-bond interaction with 
two consecutive amino acid residues (i.e. Gln137 and Glu138). Further, the list of amino 
acids interacting with de novo designed molecules and BI-224436 are given in Table S1 
(Supplementary data). Collectively, the analyses of the docking interaction map provide a 
possible knowledge of molecular interaction mechanism of designed ligands which may 
exhibit for inhibiting the HIV-1 integrase protein with better efficacy in comparison to the 
existing compound. Further, these above-mentioned docking complexes are subjected to all-
atom MD simulations analyses in order to understand the dynamic nature of designed 




















Figure 5. Binding orientation and location of identified all 4 proposed compounds and BI-
224436 obtained in docking study  
 
3.3 Comparative study of binding interactions with existing literature 
It is obvious that due to the diversity in the structural framework of all four newly designed 
compounds (H1, H2, H3 and H4 in Figure 2) demonstrate a somewhat different molecular 
interaction profile with HIV-1 integrase protein. For instance, the present study finding 
reveals some novel molecular interaction profiles for the de novo designed compounds. 
However, few observations also noted comparable interaction patterns and residues 
involvement with four compounds. An earlier study has explained the importance of residue 
Glu87 in interactions with a small molecule such as tetra-acetylated inhibitor (2E)-3-[3,4-
bis(acetoxy)phenyl]-2-propenoate-N-[(2E)-3-[3,4-bis(acetyloxy)phenyl]-1-oxo-2-propenyl]-
l-serine methyl ester [73]. The same amino acid (Glu87) seems to be engaged as a central 
linker to form an integrase dimer [73]. In the present study, H1 and H2 reveal the strong 
interaction affinity with the residue Glu87 through the formation of H-bond interaction and 
hydrophobic contact. Additionally, in a computational study, a few HIV-1 integrase inhibitors 
were studied through 3D QSAR, docking and molecular dynamics simulation which 
explained the importance of Gln177 residue as a favorable hydrogen bond donor that is 








involved in exhibiting H-bond interaction with H2. Among a number of conserved 
hydrophobic amino acid residues such as Trp132, Met178, Phe181, Phe185 are present in the 
CCD or core-core interface of HIV-1 integrase protein usually trusted to participate in the 4-
tiered π interaction for multimerization [75, 76]. The compound H2 is found to form H-bond 
interaction with Phe181 which may contribute to stabilizing the complex as well as play a 
critical role in DNA integration and viral infectivity through 4-tiered π interaction. In an 
earlier study, it has been reported the importance of the aromatic amino acid residue (Tyr83) 
for the involvement in π–π interaction [74], and this study also highlights its importance in 
terms of creation of similar (pi-pi stacking) interaction with compound H2. Moreover, this 
region also proves to be crucial due to the aromatic hydrophobic interactions. Amino residue, 
Val113 is found to be important to form H-bond interaction with H3 which can be 
substantiated by an earlier study where replacement of the same amino residue found to 
decrease the integrase catalytic activity [77]. In the present study, H4 exhibit the participation 
of residue Glu138 in H-bond interaction. Although, the presence of this amino acid in CCD 
and its importance are highlighted in different ways in different studies [78]. The residue 
definitive impact has been investigated to suppress the replication of specific drug-resistant 
(E138K) RT and impairment of HIV-1 integrase SUMOylation [79, 80]. Additionally, in 
another study, the docking interaction revealed that residue Glu138 is formed similar H-bond 
interaction profile [81]. Alltogether, the findings of the molecular docking analyses of four 
compounds establish significant molecular binding interactions as explained earlier or newly 
formed interaction profiles with the HIV-1 integrase protein complex which may suggest that 
the de novo compounds provide a better opportunity of developing therapeutic activity for 
HIV-1 integrase inhibition. 
 
3.4 Pharmacokinetics and drug-likeness analysis 
To explore the pharmacokinetic behavior of the final proposed HIV-1 integrase inhibitors, a 
number of pharmacokinetics and physicochemical properties have been calculated through 
the SwissADME web server [66] and given in Table 1. The molecular weight of all four 
molecules is found to be in the range of 311 to 443 g/mol. The oral activeness can be 
explained through the total polar surface area (TPSA) and the value is found to be 136.65, 
108.49, 83.91 and 69.39 Å2 for H1, H2, H3 and H4 respectively. Above TPSA value 
undoubtedly favors the oral activeness of the molecules. Solubility class explains that all the 
molecules are either soluble or moderately soluble in nature. The human intestinal absorption 









in the intestine. The flexibility of the molecule can be explained through its number of 
rotatable bonds and it is found to be 10, 8, 10 and 9 in H1, H2, H3 and H4 respectively.  
Moreover, the HIA and BBB are explored through the BOILED-Egg model retrieved from 
the SwissAdme server which is given in Figure 6. In this model, the molecule present in the 
albumin (white) and yolk (yellow) regions explain their intention to penetrate the HIA and 
BBB respectively. It is also reported that yellow and white regions are not mutually 
exclusive. From Figure 6, it can be seen that all the molecules except H4 show strong 
absorption in the HIA. Further, substrates (PGP+) and non-substrates (PGP-) characteristics 
of each molecule are verified and represented by blue and red circles respectively in Figure 6. 
As reported that on drives back the molecules into the intestinal lumen in the liver the PGP 
declines the efficiency of PGP+. In Figure 6, H1 and H4 are found to be in the category of 
PGP- which indicates that they belong to the non-substrate category. The other two 
molecules, H2 and H3 are found to be in PGP+ category. From the above observations, it is 
undoubtedly clear that H1, H2, H3 and H4 consist of characteristics to be the promising HIV-
1 integrase inhibitors.  
 
 










In order to check the drug-likeness of the proposed molecules, a number of parameters such 
as LE, LE_Scale, FQ and LELP have been calculated which is given in Table 1. The LE is 
calculated as per equation (1). It is illustrated that the  LE ≤ 0.4 indicates the lead-like nature 
of the molecule. Not a single proposed molecule is found to be possessing LE more than 
0.290 which clearly explains that all the molecules consist of drug-likeness characteristics.  
 
Table 1. Bioactivity and efficiency parameters of proposed HIV-Integrase inhibitors 
Molecule 1BE 2LE 3LE_Scale 4FQ 5LELP 
H1 -7.0 0.250 0.358 0.698 4.840 
H2 -6.9 0.255 0.369 0.692 7.278 
H3 -6.6 0.275 0.404 0.680 10.4 
H4 -6.6 0.289 0.416 0.696 7.804 
BI-224436 -6.6 0.200 0.307 0.651 15.95 
1Binding energy; 2Ligand efficiency; 3Ligand efficiency scale; 4Fit quality; 
5Ligand-efficiency-dependant-lipophilicity 
 
The LE_Scale of all four molecules has been calculated through equation (2) and found to be 
in the range of 0.307 to 0.416. Low LE_Scale value undoubtedly explains that H1, H2, H3 
and H4 are potential in nature. 
Being a potential molecule, the FQ (calculated using equation (3)) value should be close to 1. 
Table 1 indicates that the FQ value of H1, H2, H3 and H4 is found to be 0.698, 0.692, 0.980 
and 0.696 respectively. The above data clearly indicates that all the molecules have a strong 
binding capability to the HIV-1 integrase. 
Finally, the LELP has been calculated by using equation (4). The recommended value of the 
LELP is more than 3. The LELP value of H1, H2, H3 and H4 is found to be 4.840, 7.278, 
1.0400 and 7.804 respectively. Above LELP value undoubtedly explains that all the proposed 
molecules possess drug-like properties.  
 
 
3.5 Molecular dynamics simulation analyses  
MD simulation strategy of the protein-ligand complex is a crucial and powerful approach to 
check the dynamic behavior and the stability of the molecules. For this purpose, the proposed 









MD simulation study. The entire trajectory of each complex is used to calculate the RMSD, 
RMSF and Rg parameters.  
The RMSD of each frame corresponding to the simulation time can give a clear idea about 
the dynamic stability and the protein backbone conformational perturbations. It has been 
noticed that all the systems achieve the equilibrium state at 100ns of MD simulations. 
Backbone RMSD of each complex is calculated which is given in Figure 7. Average, 
maximum and minimum RMSD are also calculated that is given in Table 2. Manual 
inspection of the plot (Figure 7) clearly indicates that the backbone of HIV-1 integrase bound 
with proposed inhibitors and BI-224436 shows consistency during the simulation. There is no 
significant fluctuation observed in any protein-ligand complex except H1-HIV-1 integrase 
complex. Frames of each complex are stabilized within the 0.532 nm. The HIV-1 integrase 
backbone bound with H1 initially deviates within the range of 0.3 nm and finally, it achieves 
consistency around RMSD value of 0.4 nm. The backbone of HIV-1 integrase bound with 
remaining molecules is found steady throughout the simulation. The difference between the 
maximum and average RMSD is found to be 0.161, 0.105, 0.090, 0.145 and 0.087 nm bound 
with H1, H2, H3, H4 and BI-224436 respectively. The above low value clearly explains the 
less deviation of the backbone in comparison to the crystal structure. The steadiness of the 
RMSD throughout the MD simulation is clearly explained that all the proposed HIV-1 
integrase inhibitors hold the protein backbone through the binding interactions which lead to 
restricting the higher deviation.  
 
 










In the protein-ligand complex stability, the individual amino acid plays a critical role. The 
fluctuation of the singular amino acid of HIV-1 integrase has been calculated in terms of 
RMSF and depicted in Figure 8. The RMSF plot clearly indicates that all the amino acids of 
HIV-1 integrase bound with proposed molecules fluctuate in a similar pattern with few 
exceptions. It can be seen that amino residues approximately range from 135 to 155 are 
fluctuated with higher value in comparison to others. The distant fluctuation of amino acids 
in the above range might be due to their role in the binding of ligand differently. Maximum 
and minimum RMSF value is found to be 0.634 and 0.067; 0.538 and 0.066; 0.497 and 0.060; 
0.674 and 0.076; and, 0.732 and 0.067 nm for the HIV-1 integrase bound with H1, H2, H3, 
H4 and BI-224436 respectively. Above low RMSF values clearly indicate that there is no 




Figure 8. RMSF of HIV-integrase amino residues bound with H1, H2, H3, H4 and BI-
224436 
 
Moreover, per residue contribution in binding energy is an important and essential approach 
to check the important amino residues for the ligand binding. It has been observed that all the 
interacting amino residues with proposed HIV-integrase inhibitors reveal high binding energy 
with few exceptions. The average contributing binding energy of each amino residue has 
been calculated and plotted in Figure S2 (Supplementary data). In the case of HIV-1 integrase 
bound with H1 and H2, the binding energy of Phe181 has found to be negative. Another 
catalytic amino acid, Glu138 is found with negative binding energy when bound with H3 and 








and Gln177 in HIV-1 integrase-H2; Val113 in IN-H3; and, Gln137 in IN-H4 are found to 
have negative binding energy. Hence above amino residues are undoubtedly major interacting 
residues with the proposed molecules. Moreover, other amino residues are found vicinity to 
the proposed molecules also showed negative binding energy with few exceptions. In the case 
of RMSF analysis, the amino residues 115 to 155 of IN fluctuate differently when bound with 
proposed IN inhibitors. Per residue contribution analysis is clearly shows that the amino acids 
of the above range having very low range binding energy that might be the reason for 
fluctuation differently. 
 
Table 2. RMSD and RMSF of HIV-1 integrase bound with proposed inhibitors  























) Minimum 0.001 0.001 0.001 0.001 0.001 
Maximum 0.532 0.476 0.459 0.506 0.4567 








) Minimum 0.067 0.066 0.060 0.076 0.067 
Maximum 0.634 0.538 0.497 0.674 0.732 
Average 0.203 0.184 0.184 0.215 0.188 
 
The rigidness of the system can be addressed through the inspection of the radius of gyration 
value. For each protein-ligand system, the Rg value has been calculated which is given in 
Figure 9. Except for the HIV-1 integrase bound with H1 all systems are found steady during 
the MD simulation. Not a single system is found with a significant deviation in comparison to 
the crystal structure. HIV-1 integrase bound with H1 is found to show a little bit deviation 
around 50ns of MD simulation. For deep inspection about the steadiness of each system, the 
difference of maximum and minimum with average Rg value checked and found to be 10.106 
and 0.170 nm; 0.086 and 0.139 nm; 0.051 and 0.096 nm; 0.053 and 0.107 nm; and, 0.054 and 
0.102 ns for H1, H2, H3, H4 and BI-224436, respectively. All the above values are found to 
be less 0.6 nm which undoubtedly explained that no observable deviation of the system found 
throughout the simulation. Therefore, a detailed analysis of RMSD, RMSF and Rg 
parameters above has indisputably indicated that the proposed molecule retained inside the 











Figure 9. Radius of gyration of HIV-1 integrase bound with H1, H2, H3, H4 and BI-224436 
 
3.6 Post MD simulations based conformation and interactions analyses 
The binding interactions obtained in molecular docking are not always preferred because 
some molecular interactions found in the initial docking complex might lose its interaction 
integrity during the MD simulation run, or sometimes new molecular interactions also might 
appear as well. Therefore, instead of depending on molecular docking data, MD ensemble 
data are much richer and reliable, and it is proven to be a more accurate and effective 
approach to explore molecular conformations analysis. In this study, a longitudinal analysis 
of protein-ligand interactions based on the MD simulations data have been critically explored 
to understand the sustainability of the key interactions found in the MD simulation. The last 
frame of each protein-ligand complex after all-atoms 100ns MD simulation extracted and 
binding interaction profile is given in Figure 10. The molecular interactions profile analysis 
reveals that at the end of the simulation, H1 consists of two newer H-bond interactions with 
amino acid residues Tyr83 and Ala86. Few common amino acids Trp108, Phe181, and 
Val201 remain to be firmly interacted via the formation of hydrophobic contacts with H1. 
Interestingly, a new type of molecular interaction viz. salt bridge interaction has appeared 










Figure 10. Post-MD simulated interaction analyses for all proposed inhibitors including the 
standard compound BI-224436 
 
The MD simulation interactions profile of H2 shows very surprising and crucial observations. 
Most of the interactions found are new in comparison to molecular docking findings. In 
particular, the amino acid residues such as Asp54, Thr66, Ser153, Met154, and Asn155 are 
observed to form H-bond interactions during MD simulation with the help of induce fit 
energy effects that might help to create such H-bond interactions with H2. Additionally, a 
few other residues such as Asp64, Ile84, Asn155, and Leu158 establish the hydrophobic 
contacts with H2. A salt bridge formation is also observed with basic amino acid residue, 
Lys159 with H2 during MD simulation. The ligand binding interaction in the dynamic state 
reveals that H3 also forms newer types of interactions profile in respect to that found in 
docking analysis. The amino residues Ile84, Arg107, Phe181, Asn184 and Gly197 form H-
bond interactions, and Tyr83, Val180, Asn184, His185 and Ile200 found to participate in 
hydrophobic contacts. It is important to note that the new binding interactions observed in 
MD simulation are not far away from the initial binding pose / active site pocket. It can be 
said that during MD simulation, flexibility exerted to the ligand as well as protein might 
develop such a conformational state to exhibit new conformation/state of the protein-ligand 
complex for H3-integrase protein. At the end of the simulation, the molecular binding 









binding/interaction orientation in comparison to docking orientation. Precisely, residues 
Tyr83, Glu85, Arg107, and Gln177 form H-bond interactions with H4. Beside above residues 
involvement in interactions, hydrophobic contacts also form with hydrophobic residues viz. 
Val180, Phe181, and Asn184 during MD simulations. In addition, one pi-stacking interaction 
is observed between residue Phe181 and H4 based on MD simulation interaction analysis. 
The binding orientation of standard compound BI-224436 is checked at the end of the MD 
simulation which reveals that residue Arg107 form H-bond interaction and salt bridge with 
compound BI-224436, and residues Gln177, Val180, and Phe181 are attributed to participate 
in hydrophobic contacts. Although, there are some new findings in terms of participation of 
amino acids involvement based on MD simulations interaction analyses. However, few 
common amino acid residues are also found to be anchored with the identified compound as 
observed in molecular docking analysis. The above mentioned observations for all protein-
ligand complexes suggest that the difference in the structural features of identified inhibitors 
can lead to govern different internal dynamics in HIV-1 integrase protein, specifically at the 
CCD region. Overall, all the aforementioned molecular interactions obtained in MD 
simulation study indicate that binding of proposed inhibitors generates an obvious impact on 
the conformational changes in CCD region of HIV-1 integrase protein which is induced to 
bring forth new intermolecular interactions during MD simulation. Furthermore, such 
observations suggest that newly de novo designed inhibitors might act as allosteric inhibitors 
because identified compounds (H1-H4) are essentially found to interact with residues at the 
allosteric site or surrounding residues present in the allosteric site of HIV-1 integrase protein. 
As the reference standard compound BI-224436 binds to a large allosteric region extending 
from amino acid residues 168 to 178 for inhibiting 3’-end processing activity. Hence, it is 
highly expected that identified compounds also interact with amino residues at the allosteric 
region or its close proximity. Post-MD simulation complexes are found to exert the binding 
interactions with critical amino residues present in the allosteric site HIV-1 integrase.            
 
3.7 Binding energy through MM-PBSA approach 
The binding affinity of the proposed molecules and BI-224436 towards the HIV-1 integrase 
has been assessed through the calculation of binding free energy using the MM-PBSA 
approach. For this purpose, the entire trajectory of each system is considered. It is illustrated 
that binding free energy obtained through MM-PBSA approach is more authentic in 
comparison to the binding energy derived from any other static frame such as molecular 









given in Figure 11. Moreover, the average, maximum and minimum binding free energy are 
also extracted which is given in Table 3. Lower the binding free energy of the molecule 
explains stronger attraction towards the HIV-1 integrase. On close inspection, it can be seen 
that H1 shows the highest affinity with the average binding energy value of -175.122 
Kcal/mol followed by H2 with -62.979 Kcal/mol, H3 with -55.883 Kcal/mol, H4 with -
38.758 Kcal/mol, and, BI-224436 with -26.927 Kcal/mol. It is worth to be noted that BI-
224436 shows the lowest affinity in comparison to the proposed HIV-1 integrase inhibitors. 
From Figure 11, it can be seen that except H2, all molecules show consistency in binding 
energy for each frame during the simulation. Although estimation of the binding energy of 
H2 quite fluctuates for the different frame but not a single frame is found to have binding free 
energy 0 or higher than 0 Kcal/mol. Moreover, it has been observed that the Coulomb or 
electrostatic interaction and van der Waals interaction energy mainly contribute to 
accomplish higher binding free energy. Therefore, all proposed HIV-1 integrase inhibitors are 
found to show strong affection towards the protein and possess enough strength for the 
inhibition. 
 
Table 3. Maximum, minimum and average Van der Waals, electrostatic and binding free 
energies of H1, H2, H3, H4 and BI-224436 




Minimum -38.009 -38.264 -49.121 -36.234 -39.001 
Maximum -6.963 11.543 0.000 4.3234 -2.312 
Average -25.139 -14.660 -27.292 -12.871 -9.692 
Electrostatic 
(Kcal/mol) 
Minimum -242.057 -182.664 -66.733 -69.509 -54.327 
Maximum -52.455 21.556 8.409 8.342 10.347 




Minimum -264.116 -191.441 -103.095 -85.171 -42.744 
Maximum -78.678 -2.162 -17.644 -6.696 -5.749 












Figure 11. Binding free energy of H1, H2, H3, H4 and BI-224436 bound with HIV-1 
integrase 
 
4. Future prospects 
Application of the pharmacoinformatics tools and algorithms in the drug discovery research 
brought in new benchmarks to identify promising chemical compounds for a specific target. 
There is no denial that pharmacoinformatics approaches are the boost to enhance the drug 
discovery pipeline. Proposed four molecules show strong binding affection towards the HIV-
1 integrase through molecular docking, in-silico pharmacokinetics and MD simulation 
studies. Further, to check the potentiality of proposed molecules against HIV-1 integrase a 
number of experimental validations are needed. The thermal shift assay can be used to verify 
the binding affinity of the molecules. The kinetic study is the perfect approach to check the 
binding and unbinding mechanism of the molecules. The molecules may need further 




The structure-based designing such as de novo approach in LigBuilder is used to identify 
novel and potential chemical components for successful inhibition of HIV-1 integrase. For 
this purpose, a known inhibitor bound in the x-ray crystal structure of the HIV-1 integrase has 









de novo strategy with the help of LigBuilder, installed in a Linux-based server. Followed by 
the removal of duplicate molecules, a number of criteria are imposed to narrow down the 
chemical space. Initially, after verifying the LoF and Veber’s rule all molecules are docked 
and the binding energy is compared with BI-225536. Molecules having better binding energy 
than BI-225536 are considered for further assessment. The toxic, mutagenic, irritant and 
carcinogenic molecules are identified through the TOPKAT and removed. Further, the drug-
likeness and pharmacokinetics characteristics are assessed. Finally, the binding interactions 
of remaining molecules explored and four molecules are found to be promising HIV-1 
integrase inhibitors. A number of catalytic amino residues are found to form strong binding 
interactions with the proposed molecules. Finally, the characteristics in the dynamic 
environment of each molecule are explored through a 100ns MD simulation study. The 
number of parameters included RMSD, RMSF and Rg which are calculated from the entire 
trajectory on successful completion of the MD simulation. All the above parameters 
undoubtedly explain that proposed molecules are capable enough to retain inside the receptor 
cavity of HIV-I integrase. Finally, the binding free energy of each molecule including BI-
224436 is calculated using the MM-PBSA approach. Interestingly it is found that all 
proposed molecules show higher binding affection towards the HIV-1 integrase in 
comparison to the BI-224436. Hence, it can be concluded that newly designed and proposed 
molecules might be important to inhibit the HIV-1 integrase subjected to experimental 
validation. 
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